Neogen expects regulatory review of Genomics sale to Zoetis to conclude in early 2027
ZTS•Neogen expects regulatory review of its sale of the global Genomics business to Zoetis to conclude in early 2027. Zoetis has offered to divest certain Australian assets to help secure clearance.
1. Review continues
Australian and New Zealand competition authorities continue reviewing Zoetis’ acquisition of Neogen’s global Genomics business. Zoetis has offered to divest certain Australian assets to help secure clearance. The definitive sale agreement was announced on March 2, 2026, and completion remains subject to customary closing conditions and regulatory approvals.
